Michael J Buege

8PUBLICATIONS
43CO-AUTHORS
Haematological tumoursPredictive and prognostic markersEnvironmental epidemiologyCancer therapy (excl. chemotherapy and radiation therapy)Pharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Sep 22, 2023
Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study.

David A Qualls, Nicholas Lambert, Paolo F Caimi

|Jun 12, 2023
Time to progression of disease and outcomes with second-line BTK inhibitors in relapsed/refractory mantle cell lymphoma.

Diego Villa, Aixiang Jiang, Carlo Visco

|Mar 27, 2023
Low incidence of cardiotoxicity in patients with non-Hodgkin lymphoma receiving EPOCH after prior anthracycline exposure.

Michael J Buege, Esther Drill, Steven M Horwitz

|Feb 22, 2023
A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma.

Yazeed Sawalha, Subir Goyal, Jeffrey M Switchenko

|Nov 17, 2021
Successful implementation of outpatient R ± DHAX (rituximab, dexamethasone, oxaliplatin, cytarabine) for select patients with lymphoma: a single-center experience.

Terry K Pak, Brianne N Dixon, Michael J Buege

|Jan 18, 2021
Outpatient clinical pharmacy practice in the face of COVID-19 at a cancer center in New York City.

Prakirthi Yerram, Jennifer Thackray, Lisa R Modelevsky

Pageof 2

Frequent Collaborators

3 joint publications

Tim J Peterson

2 joint publications

Jason T Romancik

2 joint publications

David A Bond

2 joint publications

Anita Kumar